biointron_2

This week, computationally designed antibody therapeutics have been high on the news, leveraging advanced deep learning and AI-driven methodologies to accelerate the discovery and optimization of antibodies.

This year’s Nobel prize in chemistry was awarded last month for using computationally designing novel proteins and predicting structures! The first half of the prize was awarded to John Jumper and Demis Hassabis, who developed AlphaFold, an artificial intelligence (AI) program that can predict a protein’s shape and function from its chemical sequence.

Anti-amyloid antibodies are designed to target and remove amyloid-beta plaques in the brain, a hallmark of Alzheimer’s disease. These plaques are toxic protein clusters believed to disrupt communication between neurons, leading to cell death and cognitive decline. By binding to amyloid-beta, these antibodies aim to neutralize or clear the plaques, potentially slowing disease progression.

Recently, we have seen exciting developments in the antibody-drug conjugate (ADC) space, from cloud computing to radioisotopes.

This past week, the Biomedical Advanced Research and Development Authority (BARDA) has provided funding for several antibody-related drug development programs. BARDA is a U.S. government agency within the Department of Health and Human Services (HHS) that funds and supports the development of medical countermeasures to protect against public health threats, such as pandemics, bioterrorism, and other emergencies.

Antibody-drug conjugates (ADCs) have seen significant developments in regulatory review, with several notable announcements in the past few weeks. Innate Pharma received FDA clearance for its investigational new drug (IND) application for IPH4502, a novel topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4. Nectin-4 is a cell membrane adhesion protein overexpressed in several solid tumors, including urothelial, breast, esophageal, lung, ovarian, and pancreatic cancers, with limited expression in normal tissues.

Bispecific antibodies are rapidly transforming the therapeutic landscape, especially in oncology and autoimmune diseases. Such recombinant molecules can bind to two different antigens at the same time, offering greater specificity in targeting disease pathways. Since their introduction, the area of bispecifics has held tremendous promise in oncological cancers like multiple myeloma and lymphomas.

These past few weeks, several antibody drug startups have progressed from the pre-seed stage to final funding rounds. In the pre-seed stage, the focus is on early research, often funded by founders, grants, or angel investors. As the company progresses to the seed stage, it seeks additional funding to validate its scientific concept and develop initial prototypes, attracting early-stage venture capital.

This month provided not just one, but two FDA approvals for antibody drugs treating patients with paroxysmal nocturnal hemoglobinuria (PNH)!

We are excited to announce that Biointron will be participating in BIOPLUS-INTERPHEX KOREA 2024, which will take place from July 10 - 12, 2024, at COEX, Seoul, South Korea. This prestigious event is a key gathering for professionals in the biopharmaceutical and biotechnology industries, and we look forward to showcasing our latest advancements and engaging with industry leaders.

We are excited to announce that Biointron will be participating in the Antibody Engineering & Therapeutics US 2024 conference, taking place from December 15 - 18, 2024, at the Marriott Marquis San Diego, California. We are looking forward to showcasing our latest innovations and connecting with industry professionals.

We are pleased to announce that Biointron will be participating in The 3rd Annual Meeting of the Antibody Society of Japan, scheduled for December 9 - 11, 2024, at the Sendai International Center, Japan. This event is a significant gathering for professionals in the antibody research field, and we are excited to share our latest developments and engage with industry leaders.

We are excited to announce that Biointron will be participating in the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024, taking place from November 6-10, 2024, in Houston, Texas. You can find us at booth #515, where we look forward to showcasing our latest innovations and connecting with industry professionals.

We are delighted to announce that Biointron will be participating in PEGS Europe 2024, from November 5 - 7, 2024, at Barcelona, Spain. You can find us at booth #1102, where we look forward to showcasing our latest innovations and engaging with industry professionals.

Biointron will be participating in the Festival of Biologics 2024 - Europe, scheduled for October 15-17, 2024, at the Congress Center Basel in Switzerland. This prestigious event is a key gathering for professionals in the biologics industry, and we are eager to showcase our latest advancements and connect with industry leaders.